Applied DNA Receives Notice of Allowance on Second Patent Protecting Proprietary DNA Transfer System for Large-Scale Cotton T...
12 August 2020 - 10:00PM
Business Wire
- Newly allowed Patent Protects Methods of
Tagging Cotton Fibers During Ginning Process -
Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the
“Company”) a leader in Polymerase Chain Reaction (PCR)-based DNA
manufacturing for product authenticity and traceability solutions,
announced today that it has received a Notice of Allowance for its
U.S. Patent Application No. 14/572,552 (US 2016/0168781 A1)
entitled “Method and Device for Marking Fibrous Materials.” The
allowed claims cover methods of DNA-tagging cotton fibers while
they travel through the forced air systems found at cotton gins,
and later authenticating the DNA-tagged cotton fibers to prove
their provenance and/or authenticity all the way to finished goods.
DTS units have tagged over 300 million pounds of cotton
to-date.
The allowed patent application, which is expected to be issued
as a U.S. patent in the next few months, extends the Company’s
patent protection for its proprietary DNA Transfer System (“DTS”),
a key component of its CertainT® platform for cotton. The Company
also holds United States Patent 9,963,740 on its DTS and has
several related international patent applications pending.
“The extension of our patent protection to cover our method of
DNA-tagging cotton demonstrates our commitment to broadly protect
our CertainT platform and ensure our ability to deliver supply
chain security and authenticity to current and future CertainT
customers,” said Dr. James Hayward, president and CEO of Applied
DNA. “Despite the downturn in global economic activity that has
impacted the global textile supply chains we serve, supply chain
certainty and social responsibility remain fundamental to the
textile industry’s long-term strategy. We believe the COVID-19
pandemic has increased consumer awareness of the need for
authenticity in such textiles as those used in personal protective
equipment. When economic activity within the industry ramps, we
believe that our CertainT platform is well-positioned to address
the critical issues of traceability and authenticity in our
traditional home textiles base, as well as new apparel
opportunities currently being explored.”
“The key to the CertainT platform for cotton is the ability to
cost-effectively tag cotton in very large quantities while
concurrently collecting data that informs the supply chain down to
each individual bale – the date, time, location of tagging, the
type of cotton being tagged, among others – through the use of our
DTS to give brand owners the assurance that their cotton, their
brand, and their supply chains are secure through to their
end-customers,” said MeiLin Wan, vice president of Textile Sales at
Applied DNA. “In addition, our DTS can be permanently or
temporarily installed in essentially any gin, allowing the company
to tag cotton worldwide, with DTS units already installed in the
U.S., Egypt and Australia.”
About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable
supply chain security, anti-counterfeiting and anti-theft
technology, product genotyping and pre-clinical nucleic acid-based
therapeutic drug candidates.
Visit adnas.com for more information. Follow us on Twitter and
LinkedIn. Join our mailing list.
The Company’s common stock is listed on NASDAQ under ticker
symbol ‘APDN’, and its publicly traded warrants are listed on OTC
under ticker symbol ‘APPDW’.
Applied DNA is a member of the Russell Microcap® Index.
Forward-Looking Statements
The statements made by Applied DNA in this press release may be
“forward-looking” in nature within the meaning of Section 27A of
the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934 and the Private Securities Litigation Reform Act of
1995. Forward-looking statements describe Applied DNA’s future
plans, projections, strategies, and expectations, and are based on
assumptions and involve a number of risks and uncertainties, many
of which are beyond the control of Applied DNA. Actual results
could differ materially from those projected due to the possibility
of a failure to make timely payment on its outstanding secured
convertible notes and resulting enforcement by noteholders of
remedies on collateral which includes substantially all of Applied
DNA’s assets, its history of net losses, limited financial
resources, limited market acceptance, the uncertainties inherent in
research and development, future clinical data and analysis,
including whether any of Applied DNA’s or its partners vaccine
candidates will advance further in the preclinical research or
clinical trial process, including receiving clearance from the U.S.
Food and Drug Administration or equivalent foreign regulatory
agencies to conduct clinical trials and whether and when, if at
all, they will receive final approval from the U.S. FDA or
equivalent foreign regulatory agencies, the unknown ability to
manufacture the vaccine candidates in large quantities, the fact
that the safety and efficacy of the vaccine candidates has not yet
been established, the unknown ability of the vaccine candidates to
generate revenue or profit for Applied DNA, the fact that there has
never been a commercial drug product utilizing PCR-produced DNA
technology approved for therapeutic use, the unknown outcome of any
applications or requests to U.S. FDA or equivalent foreign
regulatory agencies, disruptions in the supply of raw materials and
supplies, and various other factors detailed from time to time in
Applied DNA’s SEC reports and filings, including our Annual Report
on Form 10-K filed on December 12, 2019, as amended on December 16,
2019 and on January 27, 2020, and our subsequent quarterly reports
on Form 10-Q filed on February 6, 2020, May 14, 2020 and August 6,
2020, and other reports we file with the SEC, which are available
at www.sec.gov. Applied DNA undertakes no obligation to update
publicly any forward-looking statements to reflect new information,
events, or circumstances after the date hereof or to reflect the
occurrence of unanticipated events, unless otherwise required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200812005220/en/
Investor contact: Sanjay M. Hurry, Exec. Director, IR and
Corp. Comms, 917-733-5573, sanjay.hurry@adnas.com Program
contact: MeiLin Wan, VP, Textile Sales, 631-240-8849,
meilin.wan@adnas.com
Web: www.adnas.com
Twitter: @APDN
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Apr 2024 to May 2024
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From May 2023 to May 2024